The article congratulates Zhiwei Chen and colleagues on the important findings of the HARMONi-6 study. The authors request clarification of two specific points for a better interpretation of the findings. The HARMONi-6 trial compared ivonescimab with chemotherapy versus tislelizumab with chemotherapy in patients with squamous NSCLC. The primary endpoint was met with a significant improvement in progression-free survival (PFS): median 11.4 months versus 6.9 months (HR 0.60; 95% CI 0.46–0.78; p < 0.0001). Benefit was consistent across all patient subgroups regardless of PD-L1 expression. In the PD-L1 <1% subgroup, median PFS was 9.9 versus 5.7 months (HR 0.55). In the PD-L1 ≥1% subgroup, median PFS was 12.6 versus 8.6 months (HR 0.66).[1][3]